Intranasal sufentanil for cancer-associated breakthrough pain

Alternate title: 
J2 - Palliat Med
Secondary title: 
T2 - Palliative medicine
Short title: 
Intranasal sufentanil for cancer-associated breakthrough pain
Authors: 
Good, P.
Jackson, K.
Brumley, D.
Ashby, M.
Volume: 
23
Start page: 
54-8
Annotations: 
Type D, Priority 5
Date: 
Jan
Year: 
2009
Accession number: 
19144765
Database: 
MEDLINE Cohort
Number: 
M1 - 1
Serial: 
1477-030X
Type of work: 
M3 - Multicenter Study
ID: 
12719
DOI: 
http://dx.doi.org/10.1177/0269216308100249
Notes: 
N1 - Good P Jackson K Brumley D Ashby M
Key words: 
Administration, Intranasal
Analgesia, Patient-Controlled
*Analgesics, Opioid/ad [Administration & Dosage]
Australia
Dose-Response Relationship, Drug
Humans
*Neoplasms/co [Complications]
*Pain/dt [Drug Therapy]
Pain/et [Etiology]
Pain Measurement
Palliative Care/mt [Methods]
Prospective Studies
*Sufentanil/ad [Administration & Dosage]
Treatment Outcome
0 (Analgesics, Opioid)
AFE2YW0IIZ (Sufentanil)
Types of evidence: 
Type D
Priorities of Care: 
Priority 5: Plan and do